Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients.

Abstract

Extraordinary progress has been made over the last decade in the treatment of multiple myeloma with the incorporation of new drugs, particularly proteasome inhibitors, immunomodulators, and monoclonal antibodies. The combined use of innovative drugs, already in the first lines of treatment, has led to an expressive increase in the survival of these patients. However, the approach to relapse remains a great challenge, and the disease continues to be incurable. In this scenario, modern immunotherapy has gained the limelight, especially with its recent use of CAR-T cells in clinical trials, as in the case of multiple myeloma, having the BCMA as the primary target. The results are impactful in the treatment of multiple myeloma patients who have had multiple relapses and are triple- and penta-refractory. In this Consensus, we have brought together a group of experts in multiple myeloma to discuss and forward their recommendations for the future, which we hope is very near, incorporating the CAR-T in our country.

• Authors: Angelo Maiolino, Luciano J Costa, Marcelo Pasquini, Edvan de Queiroz Crusoe, Afonso Celso Vigorito, Marco Aurélio Salvino, Fernanda Salles Seguro, Jayr Schmidt Filho, Vania Tietsche de Moraes Hungria
• Journal: Hematology, transfusion and cell therapy (Hematol Transfus Cell Ther) Vol. 43 Suppl 2 Pg. S30-S34 (Nov 2021) ISSN: 2531-1387 [Electronic] Brazil
• PMID: 34794794 (Publication Type: Journal Article)
• Copyright: Copyright © 2021 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. All rights reserved.